AQST News and Press, Aquestive Therapeutics Inc. From 08/03/22

Aquestive Therapeutics, Inc. (AQST) Q2 2022 Earnings Conference Call August 03, 2022 08:00 AM ET Company Participants Bennett Watson - ICR Westwicke, Investor Relations Dan Barber - Chief Executive Officer Ernie Toth - Chief Financial Officer Dr. Steve Wargac...

Aquestive Therapeutics ( NASDAQ: AQST ) stock lost as much as 8.2% to $0.81 in Wednesday trading, after the pharmaceutical company reported a Y/Y fall in Q2 revenue and and a wider loss, while also raising its FY revenue and earnings guidance. AQST after hours on Tuesd...

Aquestive Therapeutics press release ( NASDAQ: AQST ): Q2 GAAP EPS of -$0.36 in-line. Revenue of $13.27M (-13.5% Y/Y) beats by $2.7M . 2022 Guidance: Total revenue (in millions) - $46 to $49M from prior forecast $42 to $47M($46.46M consensus) For fur...

Completed EPIPHAST trial successfully demonstrating rapid and significant epinephrine exposure under a variety of real-world conditions after administration of AQST-109 (epinephrine sublingual film) Initiated EPIPHAST II trial, comparing AQST-109 to epinephrine 0.3mg IM injection (r...

WARREN, N.J., July 26, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the managemen...

WARREN, N.J., July 20, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced that it wil...

Study results for the sublingual administration of AQST-109 epinephrine oral film after consuming a peanut butter sandwich demonstrates consistent Tmax of 12 minutes Study results for swallowing AQST-109 whole immediately with water showed an unexpectedly high level of gastroint...

Aquestive Therapeutics (NASDAQ:AQST) added ~31% in the post-market Wednesday after the commercial-stage pharma company announced topline results from the first three arms of Part 3 of the randomized, open-label study for AQST-109 epinephrine oral film. The three-part crossover EPIPH...

AQST-109 is the first and only orally delivered epinephrine product candidate in clinical development Fastest median time to maximum concentration (Tmax) in studies to date at 12 minutes Study continues to show AQST-109 is safe and well tolerated Head-to-head c...

WARREN, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced that it has...